verified SJR 0,896 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Taylor and Francis Ltd.

workspace_premium Q2 — Neurology (clinical) lock Subscription

Neurodegenerative disease management

Neurodegenerative disease management is a journal indexed in SJR in Neurology (clinical) with an H index of 36. It has an SJR impact factor of 0,896 and it has a best quartile of Q2. It has an SJR impact factor of 0,896.

ISSN: 1758-2024

Publisher: Taylor and Francis Ltd.

Category: Neurology (clinical)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,896 Q2

H-index 36

Acceptance rate pie_chart

37%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,896

H-index

Docs (year)

Docs 3y

106

Total refs

1157

Cites 3y

311

Citable 3y

Cites/Doc 2y

2.95

Ref/Doc

44.5

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

B cell-directed therapies in multiple sclerosis

Working memory and memory loss in neurodegenerative disease

Decision-making impairments in Parkinson's disease as a by-product of defective cost-benefit analysis and feedback processing

Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis

Could the detection of visual disturbances associated with Parkinson's disease genes in flies lead to new treatments for the disease?

Could miRNA expression changes be a reliable clinical biomarker for Parkinson's disease?

Computer modeling with randomized-controlled trial data informs the development of person-centered aged care homes

Completed suicide in a case of clinically diagnosed progressive supranuclear palsy

Collaborative transdisciplinary team approach for dementia care

Cognitive remediation to enhance mobility in older adults: the CREM study

Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians

Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments -an update for clinicians

SHOW MORE ARTICLES

Care considerations for dementia in people with Down's syndrome: a management perspective

A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned

Antipsychotics in the management of behavioral and psychological symptoms of dementia: maximizing gain and minimizing harm

Alzheimer's pathology: should peripheral monocytes and CCR2 take center stage?

Alzheimer's disease: is the clue in the eyes?

Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy

Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening

Alexithymia in Parkinson's disease: a point of view on current evidence

Aging with multiple sclerosis: cognitive, emotional and neuropathological considerations

Advances in Abeta plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease

Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?

Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?

FAQs

Neurodegenerative disease management has an SJR of 0,896 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Neurodegenerative disease management is 37%.

Neurodegenerative disease management

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Neurodegenerative disease management?

What is the APC / publication cost?

What is the acceptance rate?